Development of a Rapid Focus Reduction Neutralization Test Assay for Measuring SARS-CoV-2 Neutralizing Antibodies.
SARS-Cov-2
antibody neutralization
high-throughput neutralization assay
neutralizing antibodies
serological assay
Journal
Current protocols in immunology
ISSN: 1934-368X
Titre abrégé: Curr Protoc Immunol
Pays: United States
ID NLM: 9101651
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
entrez:
20
11
2020
pubmed:
21
11
2020
medline:
15
12
2020
Statut:
ppublish
Résumé
SARS-CoV-2 is a recently emerged human coronavirus that has escalated to a pandemic. There are currently no approved vaccines for SARS-CoV-2, which causes severe respiratory illness or death. Defining the antibody response to SARS-CoV-2 will be essential for understanding disease progression, long-term immunity, and vaccine efficacy. Here we describe two methods for evaluating the neutralization capacity of SARS-CoV-2 antibodies. The basic protocol is a focus reduction neutralization test (FRNT), which involves immunostaining infected cells with a chromogen deposit readout. The alternate protocol is a modification of the FRNT that uses an infectious clone-derived SARS-CoV-2 virus expressing a fluorescent reporter. These protocols are adapted for use in a high-throughput setting, and are compatible with large-scale vaccine studies or clinical testing. © 2020 Wiley Periodicals LLC Basic Protocol: Focus reduction neutralization test Alternate Protocol: mNeonGreen-based focus reduction neutralization test (FRNT-mNG).
Identifiants
pubmed: 33215858
doi: 10.1002/cpim.116
pmc: PMC7864545
mid: NIHMS1649342
doi:
Substances chimiques
Antibodies, Neutralizing
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e116Subventions
Organisme : NIAID NIH HHS
ID : R38 AI140299
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI090023
Pays : United States
Organisme : NIA NIH HHS
ID : R00 AG049092
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI057266
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI127799
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI148684
Pays : United States
Organisme : NIAID NIH HHS
ID : R24 AI120942
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI148378
Pays : United States
Organisme : NIH HHS
ID : P51 OD011132
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI148576
Pays : United States
Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
J Immunol. 2020 Aug 15;205(4):915-922
pubmed: 32591393
Cell Rep Med. 2020 Jun 23;1(3):100040
pubmed: 32835303
Nature. 2020 Aug;584(7819):120-124
pubmed: 32454512
J Clin Virol. 2020 Aug;129:104468
pubmed: 32485620
Curr Protoc Microbiol. 2020 Jun;57(1):e100
pubmed: 32302069
J Virol. 2020 Sep 15;94(19):
pubmed: 32699094
Cell Host Microbe. 2016 Jul 13;20(1):83-90
pubmed: 27247001
Cell Host Microbe. 2020 May 13;27(5):841-848.e3
pubmed: 32289263
Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):12123-8
pubmed: 17620608
Annu Rev Immunol. 2013;31:705-42
pubmed: 23330954
Methods Mol Biol. 2016;1435:129-41
pubmed: 27188555
Nature. 2020 Jul;583(7815):290-295
pubmed: 32422645
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
PLoS Negl Trop Dis. 2018 Oct 24;12(10):e0006862
pubmed: 30356267
Nat Med. 2020 Jul;26(7):1033-1036
pubmed: 32398876
Nature. 2020 Aug;584(7819):115-119
pubmed: 32454513
PLoS Pathog. 2010 Feb 05;6(2):e1000757
pubmed: 20140199
Science. 2020 Aug 21;369(6506):956-963
pubmed: 32540903
Nat Commun. 2020 Aug 13;11(1):4059
pubmed: 32792628
J Clin Microbiol. 2020 May 26;58(6):
pubmed: 32229605
Emerg Infect Dis. 2020 Jul;26(7):1478-1488
pubmed: 32267220
Immunity. 2020 Jun 16;52(6):971-977.e3
pubmed: 32413330
J Virol Methods. 2010 Jan;163(1):153-6
pubmed: 19761798